Please use this identifier to cite or link to this item:
Title: EVI1 as a Prognostic and Predictive Biomarker of Clear Cell Renal Cell Carcinoma
Author: Palomero, Luis
Bodnar, Lubomir
Mateo González, Francesca
Herranz, Carmen
Espín, Roderic
Garcia Valero, Mar
Jesiotr, Marzena
Ruiz de Garibay, Gorka
Ruiz de Garibay, Gorka
López, José I.
Pujana Genestar, M. Ángel
Keywords: Càncer
Immunosupressive agents
Issue Date: 1-Feb-2020
Publisher: MDPI
Abstract: The transcription factor EVI1 plays an oncogenic role in several types of neoplasms by promoting aggressive cancer features. EVI1 contributes to epigenetic regulation and transcriptional control, and its overexpression has been associated with enhanced PI3K-AKT-mTOR signaling in some settings. These observations raise the possibility that EVI1 influences the prognosis and everolimus-based therapy outcome of clear cell renal cell carcinoma (ccRCC). Here, gene expression and protein immunohistochemical studies of ccRCC show that EVI1 overexpression is associated with advanced disease features and with poorer outcome-particularly in the CC-e.3 subtype defined by The Cancer Genome Atlas. Overexpression of an oncogenic EVI1 isoform in RCC cell lines confers substantial resistance to everolimus. The EVI1 rs1344555 genetic variant is associated with poorer survival and greater progression of metastatic ccRCC patients treated with everolimus. This study leads us to propose that evaluation of EVI1 protein or gene expression, and of EVI1 genetic variants may help improve estimates of prognosis and the benefit of everolimus-based therapy in ccRCC.
Note: Reproducció del document publicat a:
It is part of: Cancers, 2020, vol. 12, num. 2
Related resource:
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
PalomeroL.pdf3.21 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons